Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is this still valid ?
Abingworth just bet $100 million that seladelpar will make it through the FDA, as they don't get any money paid back until it gets regulatory approval in the United States or EU. If you're familiar with that organization, they are extremely astute in the biotech field, and if they're betting that much on it to succeed, as the share price continues to fall in this recent biotech decline, there will come a point at which this is ridiculously underpriced, if in fact that point is not now. This is now on my radar and will be for some time, particularly if the share price continues to fall.
I used to be, and I still like it, but I'm staying away from all biotech stocks right now until the FDA seems more stable. Their capriciousness has destroyed the biotech sector in the last six months.
Any one following this company?
I sold out a while ago to buy something else, but I'm back in on Monday morning. The current price is ridiculous.
Don't ignore this quality company. It is undervalued - the only question is how quickly that value will be unlocked and reflected in the share price.
Nice movement today. I really like this one in the long-term.
If it is, it's only temporary. I like this one, as its pipeline has a large addressable population and it is supported by quality investors. I'm in at $7.15, and will happily buy anywhere around $7.00.
Very backwards since this post. Why did you think it’s was going down from 3.5?
* * $CBAY Video Chart 08-03-2020 * *
Link to Video - click here to watch the technical chart video
News: $CBAY CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
NEWARK, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live aud...
Got this from CBAY - CymaBay Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020
Just read your posting history.
Stay well.
This is very wonderful.
What happened on this stock?
Bad day?
I make lots of money everyday including Kodak last week up over 600%
Bought 2,200 sh.
When I was up $500, sold $5 strike covered calls.
Guessing I will make $1,800 in 18 calendar days if it hits $5 PPS.
This is "without" a "call out," which is, also, okay with me.
Effectively, lowers my cost for the LT and I can wash, rinse, repeat, if it stays below $5 or only goes a tiny bit above.
Stay well.
News: $CBAY CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis
The study demonstrated seladelpar to be efficacious, safe and well-tolerated 78.2% of patients on seladelpar 10 mg versus 12.5% on placebo achieved the primary composite outcome after only 3 months (p<0.0001) 27.3% of patients on seladelpar 10 mg versus zero on placebo normalize...
Read the whole news CBAY - CymaBay Announces Positive Topline Results from ENHANCE for Seladelpar in Patients with Primary Biliary Cholangitis
Already down over a dollar from the pre-market high. Yup there isn't no cure for stupid
LMAO > Call your plumber!
This POS is going backwards..flush it!
my go to $12,,,inverted head/shoulder $$$ mhop
NEWS!!!!!!!!!!!,,$7++++ mhop
This POS is going backwards..flush it!
* * $CBAY Video Chart 07-23-2020 * *
Link to Video - click here to watch the technical chart video
News: $CBAY FDA Lifts All Clinical Holds on Seladelpar
Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC Re-initiating clinical development focusing first on Phase 3 for PBC NEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on...
Read the whole news CBAY - FDA Lifts All Clinical Holds on Seladelpar
Clinical hold lifted on seladelpar INDs in NASH, PBC and PSC
https://finance.yahoo.com/news/fda-lifts-clinical-holds-seladelpar-120000271.html
NEWARK, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced today that the Food and Drug Administration (FDA) lifted clinical holds on seladelpar for all three Investigational New Drug (IND) Applications in Nonalcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC).
"This is a pivotal event for seladelpar, which had garnered a high degree of patient interest based on its promising potential for anti-cholestatic, anti-inflammatory and reduced symptom burden in patients with PBC. We are gratified and energized to be able to once again advance seladelpar into a registrational program to confirm its benefit. It is our unwavering goal to one day make it available to patients with PBC, and potentially for other chronic, inflammatory liver diseases,” said Sujal Shah, Chief Executive Officer of CymaBay. “We look forward to working with the medical and patient advocacy communities and with regulators to re-initiate development of seladelpar.”
On November 25, 2019, CymaBay halted all clinical trials of seladelpar after atypical histologic findings with no clinical or laboratory correlates were identified at the planned end-of treatment biopsy review of a 52-week Phase 2 NASH study. The FDA concurred with this decision and placed all active INDs for seladelpar on clinical hold. CymaBay committed to an in-depth investigation of these findings and comprehensive safety evaluation that concluded with an independent, expert panel review involving some of the world’s leading liver pathologists and hepatologists. The expert panel found no clinical, biochemical or histological evidence of seladelpar-related liver injury in the Phase 2 NASH study and unanimously supported re-initiating clinical development of seladelpar pending approval by the FDA. Based on the results of the investigation and the expert panel conclusions, FDA concluded that clinical trials for NASH, PBC and PSC may resume.
About CymaBay
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need. For additional information about CymaBay visit www.cymabay.com.
About Seladelpar
Seladelpar is a potent, selective, orally active PPARd agonist that is in development for the treatment of the liver diseases with the lead indication being PBC. For PBC, seladelpar has received an orphan designation from the US Food and Drug Administration (FDA) and the European Medicine Agency (EMA). Seladelpar also received Breakthrough Therapy Designation from the FDA and PRIority MEdicine status from the EMA for PBC.
Cautionary Statements
The statements in this press release regarding CymaBay’s future plans and potential clinical development activities are forward looking statements that are subject to risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties, which include, without limitation, risks related to the success, cost and timing of CymaBay's product development activities, including clinical trials. Additional risks relating to CymaBay are contained in CymaBay's filings with the Securities and Exchange Commission, including without limitation its most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. CymaBay disclaims any obligation to update these forward-looking statements except as required by law.
Public Relations Contact:
Glenn Silver
Lazar-FINN Partners
(973) 818-8198
Glenn.silver@finnpartners.com
Investor Relations Contact:
Hans Vitzthum
LifeSci Advisors, LLC
(617) 430-7578
Hans@LifeSciAdvisors.com
Mixed shelf offering? Dilution?
Earnings report today. And delay on FDA hold .
will CBAY revive from the downfall?
Nice accumulation happening. Past 1 week ran sideways, Good sign for next leg up...
iHub is not gaining attention. when FDA lifts the hold,
This is why I played CBAY.
CBAY Analysis
it should with little consolidation. When FDA removes the block on NASH, this should be $10 at least.
yup,,,over $5 institutions will be all over this,bleed the shrts,they had the chance,but no more lol mhop $$$$$
Crash up? Haha massive upside from here, expect some institutional buyers soon as well id assume. I bought this when it traded below cash, now holding for the potential!
* * $CBAY Video Chart 05-12-2020 * *
Link to Video - click here to watch the technical chart video
This might just hit your pivots.Lots of buying pressure on any dips.
where is he? he always shows up after the ticker moves to push his "analysis."
Truth in advertising. All my CBAY trades going back to Feb.
Gain: about $29,089
"Transactions for account XXXX-0794 as of 05/12/2020 11:37:26 ET"
"Date","Action","Symbol","Description","Quantity","Price","Fees & Comm","Amount",
"05/12/2020","Sell","CBAY","CYMABAY THERAPEUTICS","8752","$4.27","$0.83","$37370.21",
"05/12/2020","Sell","CBAY","CYMABAY THERAPEUTICS","400","$4.275","$0.04","$1709.96",
"05/12/2020","Sell","CBAY","CYMABAY THERAPEUTICS","929","$4.28","$0.09","$3976.03",
"04/27/2020","Sell","CBAY","CYMABAY THERAPEUTICS","6125","$1.6912","$0.23","$10358.37",
"03/19/2020","Buy","CBAY","CYMABAY THERAPEUTICS","3007","$1.26","","-$3788.82",
"03/19/2020","Buy","CBAY","CYMABAY THERAPEUTICS","1000","$1.26","","-$1260.00",
"03/19/2020","Buy","CBAY","CYMABAY THERAPEUTICS","993","$1.26","","-$1251.18",
"03/17/2020","Buy","CBAY","CYMABAY THERAPEUTICS","81","$1.31","","-$106.11",
"03/17/2020","Buy","CBAY","CYMABAY THERAPEUTICS","1125","$1.31","","-$1473.75",
"02/27/2020","Buy","CBAY","CYMABAY THERAPEUTICS","9675","$1.6456","","-$15921.18",
"02/27/2020","Buy","CBAY","CYMABAY THERAPEUTICS","200","$1.64","","-$328.00",
"02/27/2020","Buy","CBAY","CYMABAY THERAPEUTICS","125","$1.57","","-$196.25",
Transactions Total,"","","","","","",$29089.28
All out. Took the 168% gains on $15,000 worth of CBAY.
Followers
|
25
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
346
|
Created
|
04/05/14
|
Type
|
Free
|
Moderators |
CymaBay is a biopharmaceutical company developing breakthrough therapies addressing unmet medical needs. Arhalofenate, the lead product candidate, possesses two therapeutic actions in a single drug: in gout patients it is intended to prevent painful attacks in joints while at the same time promoting excretion of uric acid by the kidney, thereby removing the root cause of this debilitating disease. Arhalofenate’s differentiated profile is intended for use in a large population, with significant advantages over marketed and emerging agents which have limitations in their efficacy, tolerability, and use in patients with common comorbidities. The Company is poised to follow arhalofenate with two additional clinical stage product candidates, one in diabetes and one in mixed dyslipidemia.
Our pipeline includes three clinical stage programs. Across this portfolio, a total of 23 clinical studies, including eleven Phase 2 studies, have been completed.
Partner | Program | Research | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
---|---|---|---|---|---|---|
Arhalofenate | ![]() | |||||
MBX-8025 | ![]() | |||||
MBX-2982 | ![]() |
CymaBay Therapeutics
7999 Gateway Blvd
Suite 130
Newark, CA 94560
Sujal Shah
(917) 877-2194
investors@cymabay.com
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |